NCT01846104View on ClinicalTrials.gov

Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Ricin Poisoning
Interventions
BIOLOGICAL

50-μg booster dose RVEc

Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.

Trial Locations (1)

21702

Department of Clinical Research, USAMRIID, Frederick

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT01846104 - Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults | Biotech Hunter | Biotech Hunter